Mechanism-based Therapies directional targeted effects on human tumors have been called the most productive in three decades of significant progress in the study of carcinogenesis.
A rapidly growing number of targeted drugs can be grouped according to the mechanism of their action on one or another molecular carcinogenesis. In fact, the observed effectiveness of the drugs in each case confirms the significance of a certain property: if the property is really important for the biology of the tumor, then its inhibition should weaken the growth and progression of the tumor process.
Most anticancer drugs that target molecular-biological characteristics are designed to act on specific molecular targets that are associated with the manifestation of certain tumor properties. The specificity of the action with respect to the target was considered a virtue, because a drug with limited activity should have less nonspecific toxicity, although clinical trials had inevitable recurrence.
The explanation for this fact is that each of the main properties of tumor growth is regulated by excessive signaling systems. Therefore, a targeted therapeutic agent that inhibits one key link in a tumor may not completely disable the hallmark. This allows some tumor cells to survive and adapt to the selective effect of the applied therapy.
Such adaptation can be achieved through a mutation process, epigenetic programming, or reconstruction of the stromal microenvironment.
Given that the number of parallel signaling systems causing the trait should be limited, it is necessary to therapeutically affect all of these systems in this way to prevent the development of adaptive resistance.
The advantage of our approach is that we develop several directions of chemical cascade pathways in the cell for the development of inhibitors in several directions at the same time.
Our company conducts three directions, divided in time:
You can familiarize yourself with the details of each direction in more detail. Learn more about:
It should also be borne in mind that in response to therapy, malignant cells can reduce their dependence on some molecular biological characteristics of tumor growth, becoming more dependent on others, which is manifested by acquired resistance to drugs. This assumption is supported by recent data in which unexpected reactions to antiangiogenic therapy are found. Adaptive shifts in relation to other molecular biological characteristics of tumor growth can limit the effectiveness of analogous thearpy methods, the target of which they are.
In addition to purely therapeutic areas, we also conduct scientific and commercial activities in the following areas:
You can make an order from the available list of immunoglobulins or alaning scaning of proteins or write us a email. You can also order bioinformatics programs and get acquainted with the main publications